WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA - a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) ...

The FDA has granted orphan drug designation (ODD) and RPDD to Arbor Biotechnologies' ABO-101, to treat primary hyperoxaluria ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

Researchers uncover key mechanisms in gene regulation that may lead to better design of RNA-based medicines.

Superintendent Critchfield proposes changing Idaho's school funding formula to distribute money based on individual student ...

Investing.com's Fair Value model demonstrated its effectiveness once again, identifying a significant opportunity in BioNTech SE (NASDAQ:BNTX) that resulted in a remarkable 51% return over just six ...

Entrada has secured authorisation from the UK's MHRA to commence ELEVATE-44-201, to evaluate ENTR-601-44, aimed at treating DMD.

And yet, analysts think there is still substantial room for further growth. With four out of six analysts rating Compass a Buy, the consensus price target for this company is $11.80, a full 266.5% ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.

Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

The S&P500 closed in the red on Friday, after the week saw a massive sell-off of AI-related stocks sparked by worries around ...